JP2015516968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516968A5 JP2015516968A5 JP2015504745A JP2015504745A JP2015516968A5 JP 2015516968 A5 JP2015516968 A5 JP 2015516968A5 JP 2015504745 A JP2015504745 A JP 2015504745A JP 2015504745 A JP2015504745 A JP 2015504745A JP 2015516968 A5 JP2015516968 A5 JP 2015516968A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyran
- disease
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 65
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 22
- 208000011580 syndromic disease Diseases 0.000 claims description 22
- 239000003638 chemical reducing agent Substances 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- -1 pyrazoyl Chemical group 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 16
- 229910052796 boron Inorganic materials 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 208000006673 asthma Diseases 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- VSYYQDBTLGSLRK-UHFFFAOYSA-N 4,4-dimethoxyoxan-3-one Chemical compound COC1(OC)CCOCC1=O VSYYQDBTLGSLRK-UHFFFAOYSA-N 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- BXGOXDLHSNHTCX-LURJTMIESA-N (3s)-4,4-dimethoxyoxan-3-ol Chemical compound COC1(OC)CCOC[C@@H]1O BXGOXDLHSNHTCX-LURJTMIESA-N 0.000 claims description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 8
- BXGOXDLHSNHTCX-ZCFIWIBFSA-N (3r)-4,4-dimethoxyoxan-3-ol Chemical compound COC1(OC)CCOC[C@H]1O BXGOXDLHSNHTCX-ZCFIWIBFSA-N 0.000 claims description 7
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- VMKAFJQFKBASMU-KRWDZBQOSA-N (3as)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole Chemical compound C([C@H]12)CCN1B(C)OC2(C=1C=CC=CC=1)C1=CC=CC=C1 VMKAFJQFKBASMU-KRWDZBQOSA-N 0.000 claims description 5
- ZJQDQFFQNQUHHT-SSDOTTSWSA-N (3r)-3,4,4-trimethoxyoxane Chemical compound CO[C@@H]1COCCC1(OC)OC ZJQDQFFQNQUHHT-SSDOTTSWSA-N 0.000 claims description 4
- ZJQDQFFQNQUHHT-ZETCQYMHSA-N (3s)-3,4,4-trimethoxyoxane Chemical compound CO[C@H]1COCCC1(OC)OC ZJQDQFFQNQUHHT-ZETCQYMHSA-N 0.000 claims description 4
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 4
- 208000002249 Diabetes Complications Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 206010012655 Diabetic complications Diseases 0.000 claims description 4
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010038910 Retinitis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- KHYAFFAGZNCWPT-UHFFFAOYSA-N boron;n,n-diethylaniline Chemical compound [B].CCN(CC)C1=CC=CC=C1 KHYAFFAGZNCWPT-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 150000003890 succinate salts Chemical class 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000005412 pyrazyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- YMJJPBWCARDMCG-ZCFIWIBFSA-N (3r)-3-methoxyoxan-4-one Chemical compound CO[C@@H]1COCCC1=O YMJJPBWCARDMCG-ZCFIWIBFSA-N 0.000 claims description 2
- YMJJPBWCARDMCG-LURJTMIESA-N (3s)-3-methoxyoxan-4-one Chemical compound CO[C@H]1COCCC1=O YMJJPBWCARDMCG-LURJTMIESA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000025962 Crush injury Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 206010033307 Overweight Diseases 0.000 claims description 2
- 206010036346 Posterior capsule opacification Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010052568 Urticaria chronic Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010057469 Vascular stenosis Diseases 0.000 claims description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000024693 gingival disease Diseases 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 229910000085 borane Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000004292 cyclic ethers Chemical class 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 3
- SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical class [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621138P | 2012-04-06 | 2012-04-06 | |
| US61/621,138 | 2012-04-06 | ||
| PCT/US2013/035396 WO2013152269A1 (en) | 2012-04-06 | 2013-04-05 | Fused cyclopentyl antagonists of ccr2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017006578A Division JP2017095499A (ja) | 2012-04-06 | 2017-01-18 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516968A JP2015516968A (ja) | 2015-06-18 |
| JP2015516968A5 true JP2015516968A5 (https=) | 2016-06-02 |
| JP6110474B2 JP6110474B2 (ja) | 2017-04-05 |
Family
ID=48096365
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504745A Expired - Fee Related JP6110474B2 (ja) | 2012-04-06 | 2013-04-05 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
| JP2017006578A Pending JP2017095499A (ja) | 2012-04-06 | 2017-01-18 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017006578A Pending JP2017095499A (ja) | 2012-04-06 | 2017-01-18 | Ｃｃｒ２の縮合シクロペンチル拮抗薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8822460B2 (https=) |
| EP (1) | EP2834234B1 (https=) |
| JP (2) | JP6110474B2 (https=) |
| CN (1) | CN104619702B (https=) |
| AU (1) | AU2013243353B2 (https=) |
| CA (1) | CA2869647A1 (https=) |
| ES (1) | ES2648175T3 (https=) |
| HK (1) | HK1210150A1 (https=) |
| WO (1) | WO2013152269A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822460B2 (en) * | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
| CN105358551A (zh) * | 2012-07-19 | 2016-02-24 | 詹森药业有限公司 | Ccr2的八氢环戊并吡咯基拮抗剂 |
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| DK3297438T3 (da) | 2015-05-21 | 2022-01-17 | Chemocentryx Inc | Ccr2-modulatorer |
| CN106366091A (zh) * | 2016-08-24 | 2017-02-01 | 河北艾林国际贸易有限公司 | 海南霉素及其衍生物的用途及其海南霉素衍生物和制备方法 |
| CA3293051A1 (en) | 2017-09-25 | 2026-03-02 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| CN110028469B (zh) * | 2019-04-28 | 2022-08-09 | 南京药石科技股份有限公司 | 一种非阿片类镇痛药的关键中间体的制备方法及应用 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2132419T3 (es) * | 1993-07-23 | 1999-08-16 | Merrell Pharma Inc | Nuevos agentes de nucleosidos 9-n-biciclicos utiles como inhibidores selectivos de citocinas proinflamatorias. |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| EP1501507B1 (en) * | 2002-04-29 | 2008-05-28 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| JO2479B1 (en) | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine |
| AR045875A1 (es) * | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
| US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| JP2007534756A (ja) | 2004-04-26 | 2007-11-29 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性のテトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジンモジュレーター |
| EP1755603A4 (en) * | 2004-04-28 | 2009-03-11 | Merck & Co Inc | 3,3-DISUBSTITUTED TETRAHYDROPYRANYL CYCLOPENTYL AMIDE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY |
| US20070270417A1 (en) | 2004-07-22 | 2007-11-22 | Glaxo Group Limited | Antibacterial Agents |
| JP2008536484A (ja) * | 2005-03-11 | 2008-09-11 | メルク エンド カムパニー インコーポレーテッド | （ｒ）−４，４−ジメトキシ−ピラン−３−オールなどの（ｒ）−４，４−ジアルコキシ−ピラン−３−オールの調製方法 |
| CN101861151B (zh) | 2007-09-14 | 2014-08-13 | 梅特希尔基因公司 | 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗 |
| WO2009042193A1 (en) * | 2007-09-25 | 2009-04-02 | Abbott Laboratories | Octahydropentalene compounds as chemokine receptor antagonists |
| US8822460B2 (en) * | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
-
2013
- 2013-04-04 US US13/856,666 patent/US8822460B2/en not_active Expired - Fee Related
- 2013-04-05 HK HK15110873.4A patent/HK1210150A1/xx unknown
- 2013-04-05 CN CN201380029978.4A patent/CN104619702B/zh not_active Expired - Fee Related
- 2013-04-05 WO PCT/US2013/035396 patent/WO2013152269A1/en not_active Ceased
- 2013-04-05 JP JP2015504745A patent/JP6110474B2/ja not_active Expired - Fee Related
- 2013-04-05 ES ES13716709.4T patent/ES2648175T3/es active Active
- 2013-04-05 AU AU2013243353A patent/AU2013243353B2/en not_active Ceased
- 2013-04-05 CA CA2869647A patent/CA2869647A1/en not_active Abandoned
- 2013-04-05 EP EP13716709.4A patent/EP2834234B1/en not_active Not-in-force
-
2014
- 2014-07-24 US US14/339,918 patent/US9150532B2/en not_active Expired - Fee Related
-
2017
- 2017-01-18 JP JP2017006578A patent/JP2017095499A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516968A5 (https=) | ||
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2005519028A5 (https=) | ||
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP5411927B2 (ja) | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 | |
| JP6254075B2 (ja) | カリウムチャネル遮断剤としてのアミン誘導体 | |
| CA2457444A1 (en) | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity | |
| JP2021501151A5 (https=) | ||
| WO2003041707A1 (en) | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation | |
| JP7134178B2 (ja) | カルシウムチャネル阻害剤 | |
| AU2002347741A1 (en) | N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation | |
| US12454516B2 (en) | Nitric oxide releasing prodrugs of MDA and MDMA | |
| JP2012524107A5 (https=) | ||
| JP4575918B2 (ja) | ４−アリル−ニコチンアミド誘導体の製造方法 | |
| MX2010013058A (es) | Derivado de benceno o tiofeno y su uso como inhibidor de proteina 1 de adhesion vascular. | |
| JP5727482B2 (ja) | 神経刺激性ピペラジンの合成 | |
| JP2013505295A (ja) | Ｃｂ２受容体を選択的に調節する化合物 | |
| JPWO2010107115A1 (ja) | グリシントランスポーター阻害物質 | |
| TW202304421A (zh) | 整合應激路徑之調節劑 | |
| AU2021229414A1 (en) | Synthesis of novel EP4 antagonist and use in cancers and inflammations | |
| JP2022540922A5 (https=) | ||
| JP7746266B2 (ja) | 新規ピロール化合物 | |
| JP5642149B2 (ja) | ヒスタミンｈ３受容体モジュレーターの調製プロセス | |
| JP7168456B2 (ja) | インドリン誘導体およびそれらを使用するならびに生産する方法 | |
| JP6569678B2 (ja) | ２−アミノチアゾール誘導体またはその塩 |